ProQR Therapeutics N.V. (PRQR) and argenx SE (NASDAQ:ARGX) Comparison side by side

This is a contrast between ProQR Therapeutics N.V. (NASDAQ:PRQR) and argenx SE (NASDAQ:ARGX) based on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ProQR Therapeutics N.V. 11 0.00 N/A -1.23 0.00
argenx SE 131 0.00 N/A -1.73 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.


Table 2 provides us ProQR Therapeutics N.V. and argenx SE’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ProQR Therapeutics N.V. 0.00% -53.9% -43.8%
argenx SE 0.00% 0% 0%

Analyst Recommendations

In next table is delivered ProQR Therapeutics N.V. and argenx SE’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ProQR Therapeutics N.V. 0 0 0 0.00
argenx SE 0 0 2 3.00

Competitively argenx SE has a consensus price target of $171.5, with potential upside of 37.32%.

Insider and Institutional Ownership

Institutional investors owned 68.5% of ProQR Therapeutics N.V. shares and 55.81% of argenx SE shares. Insiders owned 20% of ProQR Therapeutics N.V. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ProQR Therapeutics N.V. 5.15% -6.99% -20.18% -41.23% 32.03% -44.36%
argenx SE -1.84% -1.67% 13.7% 35.71% 53.91% 46.21%

For the past year ProQR Therapeutics N.V. has -44.36% weaker performance while argenx SE has 46.21% stronger performance.


On 5 of the 7 factors argenx SE beats ProQR Therapeutics N.V.

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa. The company was founded in 2012 and is headquartered in Leiden, the Netherlands.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Shire International GmbH; and Bayer AG. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.